Intracardiac impedance and its applications

• US 8,494,618 B2
• Filed: 08/22/2005
• Issued: 07/23/2013
• Est. Priority Date: 08/22/2005
• Status: Active Grant

• Current Assignee: Cardiac Pacemakers Incorporated (Boston Scientific Corporation)
• Original Assignee: Cardiac Pacemakers Incorporated (Boston Scientific Corporation)
• Inventors: Zhang, Yunlong, Gilkerson, James O., Zhang, Yongxing, Moon, Boyce
• Primary Examiner(s): Lavert, Nicole F
• Application Number:
  US11/208,922
• Publication Number:
  US 20070043394A1
• Time in Patent Office: 2,892 Days
• Field of Search: 600/509, 600/515, 607/18
• US Class Current: 600/509
• CPC Class Codes: A61N 1/3621 for treating or preventing abnormally high heart rate
• CPC Class Codes: A61N 1/36521 the parameter being derived from measurement of an electrical impedance
• CPC Class Codes: A61N 1/3925 Monitoring; Protecting
• CPC Class Codes: A61N 1/39622 Pacing therapy

Abstract

A system to measure intracardiac impedance includes implantable electrodes and a medical device. The electrodes sense electrical signals of a heart of a subject. The medical device includes a cardiac signal sensing circuit coupled to the implantable electrodes, an impedance measurement circuit coupled to the same or different implantable electrodes, and a controller circuit coupled to the cardiac signal sensing circuit and the impedance measurement circuit. The cardiac signal sensing circuit provides a sensed cardiac signal. The impedance measurement circuit senses intracardiac impedance between the electrodes to obtain an intracardiac impedance signal. The controller circuit determines cardiac cycles of the subject using the sensed cardiac signal, and detects tachyarrhythmia using cardiac-cycle to cardiac-cycle changes in a plurality of intracardiac impedance parameters obtained from the intracardiac impedance signal.

Claims

1. A system comprising:

a medical device including;

a cardiac cycle sensing circuit, the sensing circuit configured to provide a sensed cardiac cycle;

an impedance measurement circuit configured to provide an intracardiac impedance signal; and

a controller circuit coupled to the impedance measurement circuit, the controller circuit configured to detect tachyarrhythmia from the intracardiac impedance signal using at least two of;

a cardiac-cycle-to-cardiac-cycle change in a value of a baseline intracardiac impedance value calculated, for a particular cardiac cycle, to represent the baseline intracardiac impedance for that particular cardiac cycle;

a cardiac-cycle-to-cardiac-cycle change in a value of maximum intracardiac impedance value calculated, for a particular cardiac cycle, to represent the maximum intracardiac impedance for that particular cardiac cycle; and

a cardiac-cycle-to-cardiac-cycle change in a slope value of the intracardiac impedance waveform signal, for a particular cardiac cycle, the slope value measured at a time corresponding to one-half of a time interval over which a maximum intracardiac impedance change occurs during that particular cardiac cycle.

2. The system of claim 1, wherein the controller circuit is configured to detect tachyarrhythmia using at least one of:

a cardiac-cycle-to-cardiac-cycle change in an area between the intracardiac impedance signal waveform and the baseline intracardiac impedance value, wherein the area is calculated, for a particular cardiac cycle, to represent the area corresponding to that particular cardiac cycle; and

a cardiac-cycle-to-cardiac-cycle change in a time interval of maximum intracardiac impedance change, wherein the time interval is calculated, for a particular cardiac cycle, to represent the time interval corresponding to that particular cardiac cycle.

3. The system of claim 1, wherein the medical device includes a memory circuit to store intracardiac impedance parameters measured in accordance with at least one cardiac cycle, and wherein the controller circuit is further operable to detect tachyarrhythmia using a change from stored intracardiac impedance parameters and measured intracardiac impedance parameters.

4. The system of claim 3, wherein the medical device is configured to store at least one trend for at least one intracardiac impedance parameter.

5. The system of claim 1, wherein the medical device is implantable and further includes a communication circuit to communicate at least one trend for at least one intracardiac impedance parameter to an external device, and wherein the external device is in communication with a communication network.

6. The system of claim 5, wherein the external device includes a display, and wherein the external device is further operable to display intracardiac impedance information.

7. The system of claim 1, wherein the medical device includes a therapy circuit coupled to the controller circuit, wherein the controller circuit is operable to initiate a therapy upon detection of tachyarrhythmia.

8. The system of claim 7, further including at least one electrical lead comprising implantable electrodes, and wherein the implantable electrodes includes at least one coil shock electrode located distally to other electrodes on the lead, the coil shock electrode adaptable for placement in a right ventricle of a heart.

9. The system of claim 7, further including at least one electrical lead comprising implantable electrodes, and wherein the implantable electrodes includes at least one coil shock electrode located proximally to other electrodes on the lead, the coil shock electrode adaptable for placement in a superior vena cava.

10. The system of claim 1, comprising implantable electrodes, and wherein the implantable electrodes includes at least one electrode adaptable for placement in a left atrium of the heart.

11. The system of claim 1, comprising implantable electrodes, and wherein the implantable electrodes includes at least one electrode adaptable for placement in a left ventricle of the heart.

12. A method comprising:

sensing cardiac cycles of a patient;

sensing intracardiac impedance to obtain an intracardiac impedance waveform;

measuring intracardiac impedance parameters from the waveform including at least two of;

a cardiac-cycle-to-cardiac-cycle change in a value of a baseline intracardiac impedance value calculated, for a particular cardiac cycle, to represent the baseline intracardiac impedance for that particular cardiac cycle;

a cardiac-cycle-to-cardiac-cycle change in a value of maximum intracardiac impedance value calculated, for a particular cardiac cycle, to represent the maximum intracardiac impedance value for that particular cardiac cycle; and

a cardiac-cycle-to-cardiac-cycle change in a slope value of an intracardiac impedance waveform signal, for a particular cardiac cycle, the slope value measured at a time corresponding to one-half of a time interval over which a maximum intracardiac impedance change occurs during the particular cardiac cycle; and

detecting tachyarrhythmia using at least one change in the intracardiac impedance parameters.

13. The method of claim 12, wherein measuring intracardiac impedance parameters includes measuring, for a particular cardiac cycle, a cardiac-cycle-to-cardiac-cycle change in a value of an area between the sensed intracardiac impedance signal waveform and the baseline intracardiac impedance value, wherein the change in area value is measured to represent the area value corresponding to the particular cardiac cycle.

14. The method of claim 12, wherein measuring intracardiac impedance parameters includes measuring, for a particular cardiac cycle, a cardiac-cycle-to-cardiac-cycle change in a time interval from when a sensed intracardiac impedance signal waveform exceeds the measured baseline intracardiac impedance value to the time it reaches the maximum intracardiac impedance value, wherein the change in the time interval is measured to represent the time interval value for that particular cardiac cycle.

15. The method of claim 12, wherein sensing cardiac cycles and sensing intracardiac impedance includes sensing cardiac cycles and intracardiac impedance using an implantable medical device (IMD).

16. A method comprising:

sensing electrical cardiac signals of a subject;

detecting tachyarrhythmia and determining whether the tachyarrhythmia is ventricular tachycardia or ventricular fibrillation, or supraventricular tachycardia using the electrical cardiac signals;

sensing an intracardiac impedance signal during the tachyarrhythmia;

determining whether the tachyarrhythmia is stable using intracardiac impedance parameters derived from the intracardiac impedance signal wherein the intracardiac impedance parameters include at least two of;

a cardiac-cycle-to-cardiac-cycle change in a value of a baseline intracardiac impedance value calculated, for a particular cardiac cycle, to represent the baseline intracardiac impedance for that particular cardiac cycle;

a cardiac-cycle-to-cardiac-cycle change in a value of maximum intracardiac impedance value calculated, for a particular cardiac cycle, to represent the maximum intracardiac impedance for that particular cardiac cycle; and

a cardiac-cycle-to-cardiac-cycle change in a value of a slope of the intracardiac impedance waveform signal, for a particular cardiac cycle, the slope value measured at a time corresponding to one-half of a time interval over which a maximum intracardiac impedance change occurs during that particular cardiac cycle; and

providing a shock therapy to the subject if the tachyarrhythmia is ventricular tachycardia or fibrillation and is unstable, and providing anti-tachycardia pacing (ATP) therapy to the subject if the tachyarrhythmia is ventricular tachycardia or fibrillation and is stable.

18. The method of claim 16, further including providing a therapy to the subject if the tachyarrhythmia is supraventricular tachycardia and unstable and withholding a therapy if tachyarrhythmia is supraventricular tachycardia and stable.

17. The method of 16, wherein providing ATP therapy to the subject if the tachyarrhythmia is ventricular tachycardia or fibrillation and stable includes providing ATP therapy before resorting to shock therapy if ATP does not mitigate the tachyarrhythmia.

19. The method of 16, wherein determining whether the tachyarrhythmia is stable using the intracardiac impedance signal includes measuring the intracardiac impedance parameters from a sensed intracardiac impedance signal waveform in association with cardiac cycles.

20. The method of 16, wherein sensing the electrical cardiac signals and sensing the intracardiac impedance signal includes sensing using an IMD, and wherein providing a shock therapy includes providing shock therapy using an IMD.

21. A method comprising:

sensing cardiac cycles of a patient;

sensing intracardiac impedance using an IMD to obtain an intracardiac impedance waveform;

measuring intracardiac impedance parameters from the waveform including at least two of;

a cardiac-cycle-to-cardiac-cycle change in a value of a baseline intracardiac impedance value calculated, for a particular cardiac cycle, to represent the baseline intracardiac impedance for that particular cardiac cycle;

a cardiac-cycle-to-cardiac-cycle change in a value of maximum intracardiac impedance value calculated, for a particular cardiac cycle, to represent the maximum intracardiac impedance for that particular cardiac cycle; and

a cardiac-cycle-to-cardiac-cycle change in a value of a slope of the intracardiac impedance waveform signal, for a particular cardiac cycle, the slope value measured at a time corresponding to one-half of a time interval over which a maximum intracardiac impedance change occurs during the particular cardiac cycle; and

deeming that a cardiac decompensation event occurred using at least one change in the intracardiac impedance parameters.

22. The method of claim 21, wherein the method further includes monitoring heart rate of the patient to detect tachycardia, and wherein deeming that a cardiac decompensation event occurred includes detecting a decrease in cardiac performance in the absence of tachycardia using the change in the intracardiac impedance parameters measured between multiple cardiac cycles.

23. The method of claim 22, wherein measuring intracardiac impedance parameters includes measuring, for a particular cardiac cycle, a cardiac-cycle-to-cardiac-cycle change in an area between the intracardiac impedance waveform and a baseline impedance value, wherein the measured area value represents the area corresponding to that particular cardiac cycle, and wherein detecting a decrease in cardiac performance includes detecting a decrease in the measured area.

24. The method of claim 22, wherein measuring intracardiac impedance parameters includes measuring, for a particular cardiac cycle, a cardiac-cycle-to-cardiac-cycle change in a time interval of maximum intracardiac impedance change measured to represent the time interval for that particular cardiac cycle, and wherein detecting a decrease in cardiac performance includes detecting an increase in the measured time interval.

25. The method of claim 21, further including adjusting a therapy provided to the patient by the IMD based at least in part on an occurrence of cardiac decompensation.

26. A method comprising:

sensing cardiac cycles of a patient using an implantable medical device (IMD);

sensing intracardiac impedance using the IMD to obtain an intracardiac impedance waveform;

measuring intracardiac impedance parameters from the waveform including at least two of;

a cardiac-cycle-to-cardiac-cycle change in a value of a baseline intracardiac impedance value calculated, for a particular cardiac cycle, to represent the baseline intracardiac impedance for that particular cardiac cycle;

a cardiac-cycle-to-cardiac-cycle change in a value of maximum intracardiac impedance value calculated, for a particular cardiac cycle, to represent the maximum intracardiac impedance for that particular cardiac cycle; and

a cardiac-cycle-to-cardiac-cycle change in a value of a slope of the intracardiac impedance waveform signal, for a particular cardiac cycle, the slope value measured at a time corresponding to one-half of a time interval over which a maximum intracardiac impedance change occurs during the particular cardiac cycle; and

trending changes in the plurality of intracardiac impedance parameters, wherein the changes are measured between multiple cardiac cycles.

27. The method of claim 26, wherein the method further includes changing at least one therapy parameter of the IMD according to the trending.

28. The method of claim 26, wherein the method further includes deeming that cardiac remodeling has occurred according to the trending.